- Home
- INDP vs TLPH Comparison
INDP vs TLPH Comparison
Compare INDP & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INDP | TLPH |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 37.9M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | INDP | TLPH |
|---|---|---|
| Price | $1.87 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 22.8K | ★ 197.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.27 | $0.38 |
| 52 Week High | $13.24 | $1.57 |
Technical Indicators
Market Signals| Indicator | INDP | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 40.66 | 49.87 |
| Support Level | $1.65 | $0.86 |
| Resistance Level | $2.18 | $1.03 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 20.20 | 57.12 |
Price Performance
Historical ComparisonAbout INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.